Reassessing the Role of Surrogate Endpoints in Drug Development for Heart Failure

With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal trends suggests an increasing rate of disagreemen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circulation
Autors principals: Greene, Stephen J., Mentz, Robert J., Fiuzat, Mona, Butler, Javed, Solomon, Scott D., Ambrosy, Andrew P., Mehta, Cyrus, Teerlink, John R., Zannad, Faiez, O’Connor, Christopher M.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205720/
https://ncbi.nlm.nih.gov/pubmed/30354535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.034668
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars